samedan logo
 
 
 
spacer
home > pmps > winter 2001 > preventive medicine - why the pharmaceutical industry needs to invest in prevention and cure to ensure effective brande protection
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preventive Medicine - Why the Pharmaceutical Industry Needs to Invest in Prevention and Cure to Ensure Effective Brande Protection

Historically, pharmaceutical companies have tended to adopt a pragmatically conservative approach to problems of brand infringement and counterfeiting. Whilst they are ready to act whenever threats to public safety arise, they are understandably reluctant to publicise such incidents for fear of adverse effects on consumer confidence and share prices. However, a reactive approach to brand protection is becoming increasingly untenable - the changing value and role of pharmaceutical brands and the globalisation of the market present issues that demand a more comprehensive protection strategy.

New Market Trends - New Risks

A number of emerging trends in the pharmaceutical industry have serious implications for manufacturers and the ways in which they protect themselves, their products and, ultimately, their profits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keith Widdowson of De La Rue Brand Protection - Pharmaceuticals
Keith Widdowson has worked in the pharmaceutical industry for nearly 20 years, in some of the largest pharma companies such as AstraZeneca and Novartis. He has recently been responsible for ensuring that major brands are truly global and he has applied key branding elements to all commercial and manufacturing components.

spacer
Keith Widdowson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical trials in the post Brexit Europe

While negotiations are still ongoing, the structure of the post-Brexit medicine testing and approval process is still unclear, and the UK government has so far ruled out an extension to the transition period which is due to come to an end at the end of this year.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement